Balaxi Pharmaceuticals logo

Balaxi Pharmaceuticals

BALAXI NSE
₹20.33 0.12 (0.59%)
Market Cap
₹112 Cr
P/E
45.18

Balaxi Pharmaceuticals (BALAXI) share price was ₹20.33 at the 28 Oct 2026 close; market capitalisation ₹112 Cr; P/E (TTM) 45.18; sector Healthcare. The share price fell 51.2% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 14.1% year on year to ₹80.68 Cr and net profit was ₹1.30 Cr, against ₹0.29 Cr a year earlier (compared with Jun 2025). Promoters held 65.99% of Balaxi Pharmaceuticals in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 44/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹20.33 −21.32 −51.19% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹112 Cr
P/E (TTM)
45.18
EBITDA
₹11.30 Cr
Return on Equity
0.57%
Debt to Equity
0.23
Book Value
₹45.12
EPS (TTM)
₹0.45
52W High
₹43.85
52W Low
₹15.20

Price-based figures as of 28 Oct 2026, 15:51 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,757.5034.864,21,683 Cr5.050.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,558.5086.752,53,748 Cr15.140.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,557.0071.541,73,334 Cr9.430.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,181.90107.801,17,891 Cr22.240.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,175.5026.161,17,257 Cr4.330.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,335.4034.591,11,463 Cr2.870.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,365.6032.721,10,321 Cr3.120.96%11.21%14.88%28,589 Cr3,356 Cr
Balaxi Pharmaceuticals (this company)
₹20.3345.18112 Cr0.452.47%0.57%3.35%284 Cr2 Cr
Median 8 companies₹1,561.5540.021,17,574 Cr4.690.72%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100. How it works →

As of 2026-10-28
v2.0.0
44 Weak
Overall score
Data confidence 100/100

Category scores

Quality Average 48
Returns, margins, earnings quality 22%
Valuation Weak 42
Cheap vs sector & own history 24%
Growth Poor 29
Sales & profit trajectory 9%
Financial Health Average 46
Solvency, leverage, coverage 9%
Momentum Poor 26
Trend strength, vol-adjusted 12%
Ownership Average 50
FII/DII/promoter flows 24%

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Stock is trading at 0.50 times its book value

Weaknesses

6
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 3.15% over past five years.
  • Company has a low return on equity of -3.58% over last 3 years.
  • Earnings include an other income of Rs.3.62 Cr.
  • Company has high debtors of 184 days.
  • Promoter holding has decreased over last 3 years: -5.23%

Technical Indicators

Oscillators

BearishNeutralBullish

Bearish

Bearish
2
Neutral
6
Bullish
1

Overall

BearishNeutralBullish

Bearish

Bearish
12
Neutral
6
Bullish
1

Moving Averages

BearishNeutralBullish

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
-5.47% higher than 3Y

change over 1 year

Net Income Growth
-94.42% lower than 3Y

change over 1 year

Cash Flow Change
87.14%

change over 1 year

EBITDA Margin Change
-64.14%

change over 1 year Operating margin 5.78% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
65.96
54.72
60.79
59.83
65.62
77.38
73.29
76.27
70.74
56.18
72.54
70.71
80.68
Expenses
57.12
43.96
47.14
46.36
55.53
66.79
69.3
63.72
66.58
55.02
69.45
70.59
76.02
Operating Profit
8.84
10.76
13.65
13.47
10.09
10.59
3.99
12.55
4.16
1.16
3.09
0.12
4.66
OPM %
13.4%
19.66%
22.45%
22.51%
15.38%
13.69%
5.44%
16.45%
5.88%
2.06%
4.26%
0.17%
5.78%
Other Income
-47.68
5.93
1.51
-0.7
-1.85
-4.11
3.94
-1.69
-1.78
1.59
0.1
2.92
-0.99
Interest
0.29
0.37
0.41
0.61
0.37
0.45
1.38
0.74
1.01
0.89
1.02
0.99
0.73
Depreciation
0.29
0.66
0.48
0.67
0.49
0.46
0.48
0.46
0.46
0.48
0.56
0.65
0.85
PBT
-39.42
15.66
14.27
11.49
7.38
5.57
6.07
9.66
0.91
1.38
1.61
1.4
2.09
Tax %
4.9%
7.92%
4.77%
4.87%
12.06%
17.41%
11.7%
10.56%
67.03%
84.06%
80.75%
56.43%
38.28%
Net Profit
-41.34
14.43
13.59
10.93
6.48
4.59
5.36
8.64
0.29
0.21
0.31
0.61
1.3
EPS (₹)
-8.07
2.82
2.65
2.01
1.17
0.83
0.97
1.57
0.05
0.04
0.06
0.11
0.24
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
14
46
231
279
336
241
293
270
280
Expenses
12
37
189
229
279
197
254
261
271
Operating Profit
2
8
43
51
57
45
38
10
9
OPM %
11%
18%
18%
18%
17%
18%
13%
3.5%
3.2%
Other Income
1
1
2
5
3
-38
-4
3
4
Interest
0
0
0
1
1
3
4
5
4
Depreciation
0
0
0
1
2
2
2
2
3
PBT
2
9
44
55
57
2
29
5
6
Tax %
19%
31%
14%
13%
19%
219%
13%
73%
—
Net Profit
2
6
38
48
46
-2
25
1
2
EPS (₹)
1.3
1.22
7.63
9.53
9.03
-0.44
4.54
0.26
0.45
Div. Payout %
0%
0%
0%
1%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
3
10
10
10
10
11
11
11
Reserves
0
18
55
103
173
190
221
238
Borrowings
0
0
4
4
13
19
53
58
Other Liabilities
3
8
31
60
43
38
25
30
Total Liabilities
6
36
100
176
240
258
310
337
Fixed Assets
0
0
2
29
41
41
41
82
CWIP
0
0
0
1
3
2
22
0
Investments
0
0
3
0
0
0
0
0
Other Assets
6
36
94
147
195
215
247
255
Total Assets
6
36
100
176
240
258
310
337
Figures in ₹ Crores

Cash Flow

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-2
-14
0
34
6
5
-35
-4
Investing
0
0
-6
-28
-11
-1
-22
-21
Financing
0
18
4
0
26
30
34
0
Net Cash Flow
-2
4
-2
6
21
34
-23
-25
Free Cash Flow
-2
-14
-3
7
-9
4
-57
-25
CFO/OP
-97
-161
6
78
32
26
-83
2
Figures in ₹ Crores

Ratios

Particulars Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
147
238
121
36
57
84
138
184
Inventory Days
—
9
29
184
189
233
173
202
Days Payable
—
64
53
92
62
82
36
51
Cash Conversion Cycle
147
183
97
129
184
235
275
335
Working Capital Days
82
181
91
92
122
142
186
236
ROCE %
—
57%
93%
60%
37%
21%
13%
3%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Balaxi Pharmaceuticals insights

57 extracted metrics + investor summaries across FY19–FY27.

Shareholding Pattern

DIIs2.56%Promot.65.99%Others7.16%Public24.29%As ofSep 2026

Documents

Frequently Asked Questions about Balaxi Pharmaceuticals

What does Balaxi Pharmaceuticals Ltd do?
Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines. [1]
Where is Balaxi Pharmaceuticals Ltd (BALAXI) listed?
Balaxi Pharmaceuticals Ltd trades as BALAXI on the NSE.
Which sector does Balaxi Pharmaceuticals Ltd belong to?
Balaxi Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Balaxi Pharmaceuticals Ltd?
Balaxi Pharmaceuticals Ltd has a market capitalisation of ₹112.24 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Balaxi Pharmaceuticals Ltd?
Balaxi Pharmaceuticals Ltd trades at a PE ratio of 45.18 as of 28 Oct 2026, on earnings per share of ₹0.45, against a book value of ₹45.12 per share.
What is the 52-week high and low of Balaxi Pharmaceuticals Ltd?
Over the last 52 weeks Balaxi Pharmaceuticals Ltd has traded between ₹15.2 and ₹43.85 as of 28 Oct 2026.
Does Balaxi Pharmaceuticals Ltd pay dividends?
Balaxi Pharmaceuticals Ltd has a dividend yield of 2.47%.
What is the Return on Equity (ROE) of Balaxi Pharmaceuticals Ltd?
Balaxi Pharmaceuticals Ltd reported a return on equity of 0.57%. Its debt-to-equity ratio is 0.23.

Company Information

Balaxi Pharmaceuticals Ltd is an IPR-based pharmaceutical Company engaged in producing, stocking, selling, and supplying branded and generic medicines. [1]

Website balaxiventures.in
Listed 2015-11-30
Face Value ₹ 2
Shares Outstanding 5,52,07,500

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BALAXI.md for Balaxi Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month